SMARCA2/4 degraders (Proteovant Therapeutics)

N/A

Report date: 2025/03/20 09:44:40
NME

Base Information

Drug NameSMARCA2/4 degraders (Proteovant Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProbable global transcription activator SNF2L2 inhibitorsSMARCA4 inhibitors
TargetsProbable global transcription activator SNF2L2Transcription activator BRG1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncopia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncopia Therapeutics IncSK Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A